Hims and Hers Health Inc. rose after the telehealth company said it was in talks with Novo Nordisk A/S to sell its ...

PCSK9 inhibition may be a suitable alternative for statin-intolerant patients, and recent data demonstrated its efficacy as ...

Weight loss drugs are set to become a disproportionate share of Lilly's business.

The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as ...

Patients presenting to the emergency department with esophageal food impaction commonly do not receive an esophageal biopsy to diagnose EoE, representing a missed diagnostic opportunity.

[NEW YORK] Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow ...

The menopausal transition is a pivotal time in women’s health, bringing about profound hormonal, metabolic and physiologic ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A ...

The new $3 billion manufacturing facility will be sited at the Leiden Bio Science Park in Katwijk, and will be Lilly's first ...

Despite no strong evidence of clinical benefit, microdosing GLP-1s will likely continue as a strategy for some to profit off of the popular drug class.

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist ...